Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections.
Nina Breinholt StærkeJoanne ReekieHenrik NielsenThomas Lars BenfieldLothar WieseLene Surland KnudsenMette Brouw IversenKasper IversenKamille FoghJacob BodilsenMaria Ruwald JuhlSusan Olaf LindvigAnne ØvrehusLone Wulff MadsenVibeke KlastrupSidsel Dahl AndersenAnna Karina JuhlSigne Rode AndreasenSisse Rye OstrowskiChristian ErikstrupThea Kolsen FischerMartin TolstrupLars ØstergaardIsik Somuncu JohansenJens Dilling LundgrenOle Schmeltz SøgaardPublished in: Nature communications (2022)
SARS-CoV-2 variants of concern have continuously evolved and may erode vaccine induced immunity. In this observational cohort study, we determine the risk of breakthrough infection in a fully vaccinated cohort. SARS-CoV-2 anti-spike IgG levels were measured before first SARS-CoV-2 vaccination and at day 21-28, 90 and 180, as well as after booster vaccination. Breakthrough infections were captured through the Danish National Microbiology database. incidence rate ratio (IRR) for breakthrough infection at time-updated anti-spike IgG levels was determined using Poisson regression. Among 6076 participants, 127 and 364 breakthrough infections due to Delta and Omicron variants were observed. IRR was 0.29 (95% CI 0.15-0.56) for breakthrough infection with the Delta variant, comparing the highest and lowest quintiles of anti-spike IgG. For Omicron, no significant differences in IRR were observed. These results suggest that quantitative level of anti-spike IgG have limited impact on the risk of breakthrough infection with Omicron.